Collagen Inhibitors
1 drugsAbout Collagen
Collagen is a major structural protein in the extracellular matrix, crucial for tissue structure and integrity.
Collagen is a therapeutic target with one FDA-approved drug, XIAFLEX, used in conditions involving collagen remodeling; there is currently no genetic evidence linking collagen directly to specific diseases.
XIAFLEX (AUXILIUM PHARMS) is the only approved drug, a biologic (other) approved in 2010, targeting an 'other' therapeutic area.
Top Collagen Drugs
AUXILIUM PHARMS is the only company with an approved drug targeting collagen.
The market is highly concentrated, indicating potential entry barriers or limited competition.
Collagen Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Collagen, using biologic (other) modality.
Exploring alternative modalities could provide a competitive advantage in this space.
Collagen Clinical Trials 29 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Collagen. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 3 | 3 | 0 | 0 | 100% |
| Phase 2 | 12 | 12 | 0 | 0 | 100% |
| Phase 3 | 5 | 4 | 1 | 0 | 80% |
| Phase 4 | 9 | 4 | 0 | 5 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Collagen Drug Approval Timeline (2010 - 2010)
The first and only drug, XIAFLEX, was approved in 2010.
The approval timeline indicates a saturated market with no recent entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 14 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Collagen. A trial counts if an approved drug acting on Collagen is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.